Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short term Debt (2020 - 2023)

GeneDx Holdings (WGS) has disclosed Short term Debt for 4 consecutive years, with $4.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Short term Debt rose 33.3% to $4.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $4.3 million, a 33.3% increase, with the full-year FY2022 number at $3.6 million, up 36.98% from a year prior.
  • Short term Debt was $4.3 million for Q1 2023 at GeneDx Holdings, up from $3.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.3 million in Q1 2023 to a low of $797000.0 in Q1 2021.
  • A 4-year average of $2.3 million and a median of $2.1 million in 2022 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 306.15% in 2022; the steepest drop was 28.28% in 2022.
  • GeneDx Holdings' Short term Debt stood at $1.4 million in 2020, then soared by 84.07% to $2.6 million in 2021, then soared by 36.98% to $3.6 million in 2022, then rose by 20.09% to $4.3 million in 2023.
  • Per Business Quant, the three most recent readings for WGS's Short term Debt are $4.3 million (Q1 2023), $3.6 million (Q4 2022), and $1.8 million (Q3 2022).